These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25225432)

  • 1. Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?
    Valcamonico F; Petrelli F; Ferrari L; Ferrari V; Grisanti S; Barni S; Berruti A
    J Clin Oncol; 2014 Nov; 32(32):3684-5. PubMed ID: 25225432
    [No Abstract]   [Full Text] [Related]  

  • 2. Words of Wisdom. Re: Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
    Kimura T; Egawa S
    Eur Urol; 2016 Apr; 69(4):754-5. PubMed ID: 26972498
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to F. Valcamonico et al.
    Smith MR; Halabi S; Small EJ
    J Clin Oncol; 2014 Nov; 32(32):3685. PubMed ID: 25225438
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
    Smith MR; Halabi S; Ryan CJ; Hussain A; Vogelzang N; Stadler W; Hauke RJ; Monk JP; Saylor P; Bhoopalam N; Saad F; Sanford B; Kelly WK; Morris M; Small EJ
    J Clin Oncol; 2014 Apr; 32(11):1143-50. PubMed ID: 24590644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone disease in prostate cancer.
    Nagrial A; Horvath L
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):3-4. PubMed ID: 20398032
    [No Abstract]   [Full Text] [Related]  

  • 6. [The role of bisphosphonate in the treatment of bone metastases from prostate cancer].
    Sallami S; Ben Rhouma S; Cherif K; Benrais N; Horchani A
    Tunis Med; 2012 Jul; 90(7):507-11. PubMed ID: 22811222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
    Pouessel D; Culine S
    Anticancer Drugs; 2012 Jan; 23(1):141-2. PubMed ID: 21934600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zometa in the treatment of diseminated prostate cancer.
    Djokic M
    Acta Chir Iugosl; 2005; 52(4):119-21. PubMed ID: 16673608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone and Men's Health. Bisphosphonate therapy for prostate cancer].
    Suzuki H; Kamiya N; Yano M; Endo T; Takano M; Kawamura K; Imamoto T; Ichikawa T
    Clin Calcium; 2010 Feb; 20(2):258-66. PubMed ID: 20118519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
    Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.
    Saad F; Higano CS; Sartor O; Colombel M; Murray R; Mason MD; Tubaro A; Schulman C
    Clin Genitourin Cancer; 2006 Mar; 4(4):257-62. PubMed ID: 16729908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
    Paparella S; Finkelberg E; Varisco D; Tondelli E; Rocco F
    Urologia; 2011; 78(4):300-4. PubMed ID: 22139807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal-related events in prostate cancer.
    Smith MR
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
    [No Abstract]   [Full Text] [Related]  

  • 15. Explaining objective responses to zoledronic acid.
    Sorscher SM
    Anticancer Drugs; 2012 Nov; 23(10):1121. PubMed ID: 23023113
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Zoledronic acid and osseous pathologies in the course of neoplasia. Part II].
    Caffo O
    Tumori; 2005; 91(6):suppl 23-7. PubMed ID: 16457163
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
    Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
    Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The if's, and's, or but's regarding bisphosphonates for prostate cancer.
    Wilt TJ; Ensrud KE
    J Natl Cancer Inst; 2007 May; 99(10):744-5. PubMed ID: 17505065
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bisphosphonate against patients with hormone refractory prostate cancer].
    Shinohara N
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():576-80. PubMed ID: 22208047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.